TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39141378
Drug: Verinurad plus
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad plus Allopurinol (12 mg plus 300 mg)
Study: 39141577
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg every 2 weeks (dose-escalation cohort)
Study: 39141577
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg every 2 weeks (dose-expansion cohort)
Study: 39141622
Drug: Sleep Restriction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Restriction Therapy (SRT) delivered over 4 weekly sessions comprising two face-to-face meetings and two telephone calls.
Study: 39141622
Drug: Sleep Hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep Hygiene Education (SHE) administered in booklet form.
Study: 39141987
Drug: soluble mRNA
Normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
Approvals — FDA: no, EMA: no, PMDA: no
Description: soluble mRNA (100 μg/animal)
Study: 39141987
Drug: C-terminal transmembrane
Normalized name: CCK C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C-terminal transmembrane mRNA (100 μg/animal)
Study: 39141987
Drug: protein vaccine
Normalized name: SARS-CoV-2 rS protein vaccine, recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: protein vaccine (400 μg/animal)
Study: 39141987
Drug: non-translatable RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-translatable RNA control (100 μg/animal)
Study: 39142110
Drug: Rigorous fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigorous fluid management using monitoring of ECW ratio by bioelectrical impedance analysis (BIA) with bolus infusion of crystalloid fluid for dehydrated patients and diuretics for overhydrated patients.
Study: 39142110
Drug: Traditional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional fluid treatment without BIA monitoring.
Study: 39142511
Drug: ENDS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENDS containing 0 mg/ml liquid nicotine
Study: 39142511
Drug: ENDS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENDS containing 8 mg/ml liquid nicotine
Study: 39142511
Drug: ENDS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENDS containing 36 mg/ml liquid nicotine
Study: 39142680
Drug: Upfront dose-reduced
Normalized name: RECOMBINANT DNA DERIVED B-DOMAIN DELETED PORCINE BLOODCOAGULATION FACTOR VIII ANALOGUE, PRODUCED IN BHK21 CELLS: DES-(753-1418)-BLOOD-COAGULATION FACTOR VIII (PROCOAGULANT COMPONENT) SUS SCROFA, GLYCOSYLATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront dose-reduced chemotherapy (25% reduction)
Study: 39142680
Drug: Full-dose chemotherapy
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose chemotherapy (fluoropyrimidine plus oxaliplatin)
Study: 39142680
Drug: Fluoropyrimidine monotherapy
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluoropyrimidine monotherapy (full-dose)
Study: 39142680
Drug: Dose-reduced chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduced chemotherapy (25% reduction)
Study: 39142718
Drug: Davoceticept (ALPN-202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Davoceticept (ALPN-202) in combination with pembrolizumab (anti-PD-1)
Study: 39142723
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonists (GLP-1 RAs)
Study: 39142926
Drug: Upadacitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib (oral Janus kinase inhibitor)
Study: 39143444
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Intervention (CBI) with walking component; participants categorized as 'sedentary' (≤ 4999 daily steps) or 'not sedentary' (≥ 5000 daily steps)
Study: 39144362
Drug: Neoadjuvant immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunochemotherapy with paclitaxel (albumin-bound) (260 mg/m2) and short-course radiotherapy
Study: 39144362
Drug: Neoadjuvant immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunochemotherapy with paclitaxel (albumin-bound) (260 mg/m2)
Study: 39145150
Drug: Mixed-frequency TENS
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-frequency TENS (2 Hz/80 Hz) administered using specially designed pants
Study: 39145700
Drug: Potential disease-modifying
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential disease-modifying therapy for LMNA-related DCM (details not specified)
Study: 39145962
Drug: Lazertinib, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib, 240 mg, once daily
Study: 39145961
Drug: POC salivary
Normalized name: Bis(POC)PMPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: POC salivary oral rinse test
Study: 39146178
Drug: Oligofructose-enriched inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oligofructose-enriched inulin (OEI) prebiotic (4 g, 3 times a day)
Study: 39146178
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 g of maltodextrin, 3 times a day)
Study: 39146397
Drug: Glucagon receptor
Normalized name: Glucagon receptor site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon receptor blockade
Study: 39146562
Drug: Sleep lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep lotion (0.24 ± 0.01% melatonin)
Study: 39146562
Drug: Sleep lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep lotion
Study: 39146801
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered before skin incision
Study: 39146801
Drug: Antibiotics administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics administered after umbilical cord clamping
Study: 39146944
Drug: High-dose hyperfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hyperfractionated radiotherapy (54 Gy in 30 fractions)
Study: 39146944
Drug: Standard-dose radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose radiotherapy (45 Gy in 30 fractions)
Study: 39146951
Drug: Adjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant pembrolizumab (200 mg IV every 3 weeks for up to 18 doses)
Study: 39147194
Drug: Topical rSm29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical rSm29 (10 µg) plus Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Study: 39147194
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Study: 39147194
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo plus Meglumine antimoniate (MA) (20 mg/kg/weight) for 20 days
Study: 39148102
Drug: Carriers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carriers of deleterious DPYD variants (c.1670C>T, c.1913T>C, c.1925T>C, c.506delC, c.731A>C, c.1740+1G>T, c.763-2A>G)
Study: 39148107
Drug: Sirolimus 1
Normalized name: sirolimus 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus 1 mg/m²/day with dose adjustments during a two-week titration period to maintain trough blood concentrations between 5 and 10 ng/ml (maximum dose 2 mg)
Study: 39148128
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous magnesium sulphate administration
Study: 39148307
Drug: Curcuminoids (Meriva)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (Meriva) 500 mg po bid for 180 days
Study: 39148430
Drug: MBL949 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBL949 (0.03 to 20 mg, single ascending dose)
Study: 39148430
Drug: MBL949 (biweekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBL949 (biweekly dosing for 14 weeks)
Study: 39148905
Drug: Erlotinib in
Normalized name: Product containing erlotinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib in combination with palliative thoracic radiotherapy (RT)
Study: 39148906
Drug: PIPAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIPAC with cisplatin 10.5 mg/m²
Study: 39148964
Drug: Topical microencapsulated
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical microencapsulated benzoyl peroxide (E-BPO) for eight weeks
Study: 39148964
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream for eight weeks
Study: 39148964
Drug: Topical microencapsulated
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical microencapsulated benzoyl peroxide (E-BPO) for four weeks after vehicle cream
Study: 39148964
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream for four weeks after E-BPO
Study: 39149474
Drug: Cabozantinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (12 weeks treatment)
Study: 39149709
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of cord blood platelet-rich plasma (CB-PRP)
Study: 39149709
Drug: Control (fellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fellow eye without treatment)
Study: 39150490
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) monotherapy for 52 weeks
Study: 39150711
Drug: Suvorexant (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (15 mg) taken at bedtime for up to 7 days
Study: 39151165
Drug: Novel module-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel module-based psychological treatment based on cognitive behavioral therapy and family therapy
Study: 39151419
Drug: Abiraterone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone treatment
Study: 39151421
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (up to 4 cycles of neoadjuvant chemotherapy followed by 3 cycles of adjuvant intravenous carboplatin/weekly paclitaxel/pembrolizumab, and maintenance pembrolizumab until progression or toxicity, maximum 20 cycles)
Study: 39151421
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (specifically for patients with PD-L1 combined positive score (CPS) ≥10)
Study: 39151421
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus chemotherapy (specifically for patients with PD-L1 CPS <10)
Study: 39151436
Drug: Fluorescence-guided bowel
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescence-guided bowel anastomosis (FGBA) with 5 mg of ICG by 2 mL intravenous bolus.
Study: 39151647
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy based on co-formulated darunavir/ritonavir (800/100 mg) plus lamivudine (300 mg)
Study: 39151647
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with darunavir/ritonavir plus tenofovir/emtricitabine (300/200 mg) or tenofovir/lamivudine (300/300 mg)
Study: 39152028
Drug: Low-dose intra-erythrocyte
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intra-erythrocyte dexamethasone sodium phosphate (approximately 5-10 mg)
Study: 39152028
Drug: High-dose intra-erythrocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intra-erythrocyte dexamethasone sodium phosphate (approximately 14-22 mg)
Study: 39152028
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (low-dose, high-dose, placebo)
Study: 39152408
Drug: Group-based antenatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based antenatal care (G-ANC)
Study: 39152477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DM and coronary microvascular dysfunction (CMD)
Study: 39152477
Drug: DM and
Normalized name: Mucus Relief DM and Overnight Cold and Flu KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM and CMD combination
Study: 39153060
Drug: Guselkumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab treatment (interleukin-23p19 subunit inhibitor)
Study: 39153779
Drug: rfhSP-D (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rfhSP-D (1 mg/kg, 2 mg/kg, or 4 mg/kg)
Study: 39153779
Drug: Routine surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine surfactant replacement therapy
Study: 39153816
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein group (2.0 g/kg per day)
Study: 39153816
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein group (1.3 g/kg per day)
Study: 39153818
Drug: Emodepside (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emodepside (30 mg total, six 5 mg tablets)
Study: 39153818
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg, one tablet)
Study: 39153911
Drug: ON-SXB (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: ON-SXB (sodium oxybate) 9 g at week 13
Study: 39154316
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg/kg bolus
Study: 39154316
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mcg/kg bolus
Study: 39155700
Drug: HRS-1780 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-1780 (5, 10, 20, 40, 60, and 80 mg)
Study: 39155700
Drug: HRS-1780 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-1780 (10, 20, and 40 mg) once daily for 7 days
Study: 39155737
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Study: 39156699
Drug: Fully-automated module
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully-automated module for radiolabeling; pH of 3.6 and precursor dose of 30 μg were used.
Study: 39157776
Drug: Mindfulness intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness intervention (6-weekly 1.5-hour sessions remotely delivered)
Study: 39158071
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in B-cell ALL
Study: 39158071
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in childhood T-cell ALL
Study: 39158071
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in young adult T-cell ALL
Study: 39158071
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in T-cell LL
Study: 39158295
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine hydrochloride 10% solution (MOB015B)
Study: 39158584
Drug: mRNA-1273 booster
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 booster dose (10 µg for 6 months-5 years; 25 µg for 6-11 years)
Study: 39158584
Drug: mRNA-1273 booster
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 booster dose
Study: 39158589
Drug: Drug-coated balloons
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-coated balloons (Passeo-18 lux DCBs)
Study: 39158670
Drug: Facilitated subcutaneous
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated subcutaneous immunoglobulin (fSCIG) 10%
Study: 39158833
Drug: Recombinant porcine
Normalized name: antihemophilic factor VIII, recombinant porcine sequence 500 (+/-) unit range INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant porcine factor VIII (rpFVIII) at an initial dose of 200 U/kg, with subsequent doses based on clinical measures; median total dose was 548.4 U/kg (range: 198-1803 U/kg) with a median of 3.0 infusions per patient.
Study: 39158893
Drug: Localized nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Localized nicardipine release implants (10 implants at 4 mg each) plus standard of care
Study: 39158894
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n=619)
Study: 39158916
Drug: HSK16149 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 40 mg/d
Study: 39158916
Drug: HSK16149 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK16149 80 mg/d
Study: 39159183
Drug: Dolutegravir (DTG)-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (DTG)-based antiretroviral therapy
Study: 39159190
Drug: Early Occupational
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Occupational Therapy Intervention program (EOTIPS)
Study: 39159648
Drug: Standard nab-paclitaxel-gemcitabine
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard nab-paclitaxel-gemcitabine treatment
Study: 39159997
Drug: BEL/RTX (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEL/RTX (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous rituximab 1000 mg at weeks 4 and 6)
Study: 39159997
Drug: BEL/PBO (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEL/PBO (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous placebo at weeks 4 and 6)
Study: 39160109
Drug: Rapid diagnosis,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid diagnosis, vaccine development and deployment, and strong funding commitment
Study: 39160146
Drug: Bimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimodal treatment (sound therapy + electrical tongue stimulation)
Study: 39160255
Drug: Immunotherapy targets
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy targets
Study: 39160459
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg twice daily for at least 8 weeks, followed by 5 or 10 mg twice daily at investigator's discretion
Study: 39160468
Drug: Tocotrienol-rich fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol-rich fraction (TRF) vitamin E, 50 mg daily for six months
Study: 39160566
Drug: REACH, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: REACH, a web-based social learning and cognitive behavior therapy (SLCBT) intervention
Study: 39161543
Drug: Lenalidomide 20
Normalized name: lenalidomide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 20 mg with intravenous obinutuzumab 1000 mg
Study: 39161801
Drug: blinded i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: blinded i.v. iron (1000 mg ferric derisomaltose)
Study: 39161870
Drug: Strict bundled
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict bundled care treatment (BCT) over the first 72 hours during acute hospital care
Study: 39161962
Drug: Varlilumab followed
Normalized name: Varlilumab
DrugBank: Varlilumab (DB11930)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varlilumab followed by Atezolizumab with palliative radiation therapy (RT)
Study: 39162035
Drug: Ketone Ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone Ester (KE) treatment (25 g D-ß-hydroxybutyrate-(R)-1,3-butanediol × 4 daily)
Study: 39162035
Drug: Ketone Ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone Ester (KE) treatment
Study: 39162632
Drug: Sequential CCTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential CCTA plus CT-FFR and CT perfusion
Study: 39162634
Drug: Lutetium 177
Normalized name: lutetium Lu 177 dotatate Injection [Lutathera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium 177 (specific dosage and duration not mentioned)
Study: 39162825
Drug: Combined qPLR
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined qPLR < 4% and NPi ≤ 2 with NSE > 60 μg/L
Study: 39162872
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + chemotherapy (SOX or CAPOX)
Study: 39162872
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + chemotherapy (SOX or CAPOX)
Study: 39163044
Drug: Maya mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maya mobile app-based cognitive behavioral therapy (CBT) intervention for 6 weeks with text message-based incentives (gain-framed, loss-framed, gain-social support)
Study: 39163044
Drug: Maya mobile
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maya mobile app-based cognitive behavioral therapy (CBT) intervention
Study: 39163362
Drug: CRP-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP-guided treatment
Study: 39163591
Drug: uTECH+YMHP (SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: uTECH+YMHP (SMS text messages informed by ML algorithm + YMHP counseling)
Study: 39163858
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) 4 g
Study: 39163971
Drug: Maple syrup
Normalized name: MAPLE SYRUP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maple syrup